SCYNEXIS, Inc. (SCYX)
- Previous Close
1.4700 - Open
1.4500 - Bid 1.5100 x 100
- Ask 1.5600 x 400
- Day's Range
1.4500 - 1.5800 - 52 Week Range
1.3500 - 3.8700 - Volume
157,721 - Avg. Volume
201,204 - Market Cap (intraday)
58.14M - Beta (5Y Monthly) 1.57
- PE Ratio (TTM)
1.11 - EPS (TTM)
1.3900 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.88
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
www.scynexis.com29
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: SCYX
Performance Overview: SCYX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SCYX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SCYX
Valuation Measures
Market Cap
58.14M
Enterprise Value
-1.14M
Trailing P/E
1.11
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.53
Price/Book (mrq)
0.80
Enterprise Value/Revenue
-0.01
Enterprise Value/EBITDA
-0.02
Financial Highlights
Profitability and Income Statement
Profit Margin
47.84%
Return on Assets (ttm)
42.01%
Return on Equity (ttm)
175.97%
Revenue (ttm)
140.14M
Net Income Avi to Common (ttm)
67.04M
Diluted EPS (ttm)
1.3900
Balance Sheet and Cash Flow
Total Cash (mrq)
74.36M
Total Debt/Equity (mrq)
20.39%
Levered Free Cash Flow (ttm)
24.73M